Skip to main content
Xiangxue Pharmaceutical Co., Ltd. logo

Xiangxue Pharmaceutical Co., Ltd. — Investor Relations & Filings

Ticker · 300147 ISIN · CNE100000Y92 LEI · 3003000D8UMO4KQ95B57 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 2,280 across all filing types
Latest filing 2024-04-29 Annual Report
Country CN China
Listing Shenzhen Stock Exchange 300147

About Xiangxue Pharmaceutical Co., Ltd.

https://www.xphcn.com

Xiangxue Pharmaceutical Co., Ltd. specializes in the research, development, manufacturing, and distribution of modern Traditional Chinese Medicine (TCM), chemical drugs, and biological products. The company is recognized for its focus on the modernization of TCM, utilizing advanced technology to standardize and enhance traditional formulas. Its flagship products include anti-viral oral liquids and Banlan'gen granules, which are widely used for respiratory health. Beyond traditional treatments, the company has expanded into high-tech biomedical fields, including precision medicine and adoptive cell therapy, specifically TCR-T cell technology for cancer treatment. Xiangxue operates a comprehensive value chain encompassing medicinal herb cultivation, pharmaceutical manufacturing, and healthcare services. By integrating digital technology with pharmaceutical expertise, the company aims to provide integrated health solutions and innovative therapies.

Recent filings

Filing Released Lang Actions
2023年度财务决算报告
Annual Report Classification · 95% confidence The document is titled '2023 年度财务决算报告' which translates to '2023 Annual Financial Settlement Report'. It contains detailed financial data for the year 2023, including revenue, profit, assets, liabilities, cash flow, and segment breakdowns. The report is audited by an accounting firm with an audit opinion mentioned. The content includes comprehensive financial statements and analysis for the full fiscal year 2023. The document length is 4012 characters, which is relatively short but contains substantive financial data, not just an announcement or certification. Therefore, it is a full annual financial report rather than a mere announcement or certification. This matches the definition of an Annual Report (10-K). FY 2023
2024-04-29 Chinese
董事会对独董独立性评估的专项意见
Board/Management Information Classification · 95% confidence The document is a statement from the board of directors regarding the independence of the company's independent directors, referencing regulatory requirements and confirming compliance. It is a specialized opinion on board/management matters rather than a financial report, audit, or announcement of voting results. The content focuses on governance and board independence evaluation, fitting the Board/Management Information category.
2024-04-29 Chinese
关于前期会计差错更正及追溯调整的公告
Audit Report / Information Classification · 95% confidence The document is a detailed announcement from 广州市香雪制药股份有限公司 regarding corrections of prior period accounting errors and retrospective adjustments. It includes extensive financial data adjustments for multiple fiscal years (2021, 2022, 2023 Q1 and half-year), covering balance sheets, profit and loss statements, and cash flow statements. The content focuses on accounting policy corrections, restatements, and their impacts on financial statements. There is no indication that this is a full annual report or quarterly report by itself, but rather a specific disclosure about accounting error corrections and restatements. This type of document aligns with an Audit Report / Information (AR) category, which includes standalone audit reports, applied accounting principles, and results of internal or regulatory stress tests, excluding full annual reports. The document is substantive and detailed, not a mere announcement or certification, so it is not Regulatory Filings (RNS) or Report Publication Announcement (RPA). Therefore, the best classification is AR with high confidence. 9M 2023
2024-04-29 Chinese
关于举行2023年度业绩网上说明会的公告
Investor Presentation Classification · 95% confidence The document is an announcement about holding an online performance briefing for the 2023 fiscal year. It references that the 2023 annual report and its summary have already been disclosed on April 30, 2024. The document invites investors to participate in a webcast meeting to discuss the annual results and ask questions. The document itself does not contain the annual report or detailed financial data but is a notice about an upcoming investor presentation event related to the annual results. According to the classification rules, announcements about meetings or presentations related to financial results fall under Investor Presentation (IP). The document length is short and it is clearly an announcement for a presentation, not the report itself or a transcript. Therefore, the correct classification is Investor Presentation (IP).
2024-04-29 Chinese
控股股东及其他关联方资金占用情况的专项说明
Audit Report / Information Classification · 95% confidence The document is a detailed special explanation report on the use of funds by controlling shareholders and related parties of 广州市香雪制药股份有限公司 for the year ending December 31, 2023. It includes audited financial data and references an audit report with a reservation opinion issued on April 29, 2024. The document is issued by a certified public accounting firm and complies with regulatory requirements from the China Securities Regulatory Commission and Shenzhen Stock Exchange. The content focuses on non-operating fund occupation and related party transactions, with detailed tables of financial figures. This is a standalone audit-related report, not a full annual report or earnings release. It is not a brief announcement or a certification letter but a substantive audit-related disclosure. Therefore, it fits the category of Audit Report / Information (AR). The document length (4856 characters) is sufficient to contain detailed financial data and explanations, supporting this classification. FY 2023
2024-04-29 Chinese
独立董事2023年度述职报告（周庆权）
Board/Management Information Classification · 95% confidence The document is a detailed annual report by an independent director of 广州市香雪制药股份有限公司 for the year 2023. It includes the director's background, attendance at board and shareholder meetings, opinions on major company decisions, communication with auditors, oversight of financial and legal matters, and overall evaluation of the company's governance and operations during the year. The content is comprehensive, covering governance, financial oversight, legal issues, and strategic decisions, consistent with a Management Report or detailed governance-related report. It is not a full Annual Report (10-K) or Audit Report (AR), nor is it a brief announcement or presentation. The document focuses on the independent director's duties and activities, which aligns best with Board/Management Information (MANG).
2024-04-29 Chinese

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.